Loading stock data…
TARA
$5.32-0.01 (-0.19%)
Market ClosedLast close May 1
Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Protara Therapeutics, Inc. in the Healthcare sector is trading at $5.32. The stock is currently 32% below its 52-week high of $7.82, remaining 5.8% above its 200-day moving average. Technical signals show neutral RSI of 58 and bullish MACD crossover, explaining why TARA maintains its current momentum and trend strength. The Whystock Score of 75/100 reflects a high-conviction bullish alignment.
Ecosystem Influences
Neutral momentum (RSI 58) — price action in range
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$5.32
Potential Upside
5%
Whystock Fair Value$5.59
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus7 analysts
Mean target$25.71+383.4%
Range$23.00 – $30.00
Fundamentals
Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$289.35M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.50
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-29.24%
Volume
Today's trading volume
394,905
Recent News
Protara Therapeutics: Q4 Earnings Snapshot
NEW YORK (AP) — Protara Therapeutics, Inc. TARA) on Tuesday reported a loss of $17.3 million in its fourth quarter. On a per-share basis, the New York-based company said it had a loss of 37 cents.
Protara Therapeutics Highlights TARA-002 NMIBC Data, FDA Plans for Lymphatic Malformations at Oppenheimer Conf
Protara Therapeutics (NASDAQ:TARA) executives outlined progress across the company’s two clinical-stage programs during a fireside chat at Oppenheimer’s 36th Annual Healthcare Life Sciences Conference, highlighting updated interim results from its ongoing non-muscle invasive bladder cancer (NMIBC) s
Protara Therapeutics Highlights Phase 2 TARA-002 Data in NMIBC, Cites Strong Response Rates at ASCO GU
Protara Therapeutics (NASDAQ:TARA) shared updated interim data from its ongoing Phase 2, open-label ADVANCED-2 trial evaluating intravesical TARA-002 in patients with high-risk non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS), with or without papillary disease. Management said
Insiders Buying Protara Therapeutics Might Wish They Invested More, Stock Gains 30%
Protara Therapeutics, Inc. ( NASDAQ:TARA ) insiders who purchased shares in the last 12 months were richly rewarded...
Protara Therapeutics: Q3 Earnings Snapshot
NEW YORK (AP) — Protara Therapeutics, Inc. TARA) on Monday reported a loss of $13.3 million in its third quarter. On a per-share basis, the New York-based company said it had a loss of 31 cents.